A Phase I, First-in-Human, Open-Label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumors
Latest Information Update: 12 Oct 2023
At a glance
- Drugs LM-061 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors LaNova Medicines Limited
- 07 Oct 2023 Status changed from recruiting to discontinued.
- 18 May 2021 Status changed from active, no longer recruiting to recruiting.
- 16 Apr 2021 Status changed from not yet recruiting to active, no longer recruiting.